BCLAF1 induces cisplatin resistance in lung cancer cells

Jiang,Tao; Liu,Bingjie; Wu,Dongping; Zhang,Feng

doi:10.3892/ol.2020.12090

BCLAF1 induces cisplatin resistance in lung cancer cells

Authors:
- Tao Jiang
- Bingjie Liu
- Dongping Wu
- Feng Zhang
View Affiliations

Affiliations: College of Life Sciences, Shanghai Normal University, Shanghai 200234, P.R. China, Department of Radiation Oncology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China
Published online on: September 11, 2020 https://doi.org/10.3892/ol.2020.12090
Article Number: 227
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatment for non‑small cell lung cancer (NSCLC) remains challenging due to frequent recurrence and the development of resistance to platinum‑based chemotherapy. The mechanism underlying NSCLC chemoresistance remains unclear. The present study aimed to investigate the mechanism of cisplatin resistance in NSCLC cells and it found that the expression of Bcl‑2‑associated transcription factor 1 (BCLAF1) was higher in the A549 cell line with cisplatin resistance (A549/DDP) by western blotting and reverse‑transcription quantitative PCR, suggesting that elevated BCLAF1 expression is associated with acquired cisplatin resistance in A549 cells. BCLAF1 was found to promote DNA damage repair in A549/DDP cells by regulating γH2A histone family member X foci formation by immunofluorescence and western blotting. BCLAF1 was also demonstrated to regulate ubiquitin‑specific peptidase 22 mRNA expression in A549/DDP cells, in addition to regulating G1 phase arrest by targeting p21 expression. Taken together, these findings suggest that BCLAF1 mediates cisplatin resistance by regulating the repair of DNA damage and p21‑mediated G1 phase arrest.

View Figures

View References

1	Wang J, Zhang ZQ, Li FQ, Chen JN, Gong X, Cao BB and Wang W: Triptolide interrupts rRNA synthesis and induces the RPL23MDM2p53 pathway to repress lung cancer cells. Oncol Rep. 43:1863–1874. 2020.PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, et al: Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 10 (Suppl 1):S1–S63. 2015. View Article : Google Scholar : PubMed/NCBI
4	Janssen-Heijnen ML, van Erning FN, De Ruysscher DK, Coebergh JW and Groen HJ: Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol. 26:902–907. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
6	Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry D: Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
7	Perse M and Večerić-Haler Z: Cisplatin-induced rodent model of kidney injury: Characteristics and challenges. Biomed Res Int. 2018:14628022018. View Article : Google Scholar : PubMed/NCBI
8	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
9	Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
10	Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB and Menck CFM: DNA repair pathways and cisplatin resistance: An intimate relationship. Clinics (Sao Paulo). 73 (Suppl 1):e478s2018. View Article : Google Scholar : PubMed/NCBI
11	Kasof GM, Goyal L and White E: Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol Cell Biol. 19:4390–4404. 1999. View Article : Google Scholar : PubMed/NCBI
12	Sarras H, Azami SA and McPherson JP: In search of a function for BCLAF1. ScientificWorldJournal. 10:1450–1461. 2010. View Article : Google Scholar : PubMed/NCBI
13	Wen Y, Zhou X, Lu M, He M, Tian Y, Liu L, Wang M, Tan W, Deng Y, Yang X, et al: Bclaf1 promotes angiogenesis by regulating HIF-1α transcription in hepatocellular carcinoma. Oncogene. 38:1845–1859. 2019. View Article : Google Scholar : PubMed/NCBI
14	Vohhodina J, Barros EM, Savage AL, Liberante FG, Manti L, Bankhead P, Cosgrove N, Madden AF, Harkin DP and Savage KI: The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export. Nucleic Acids Res. 45:12816–12833. 2017. View Article : Google Scholar : PubMed/NCBI
15	Li X, He Z, Cheng B, Fang Q, Ma D, Lu T, Wei D, Kuang X, Tang S, Xiong J and Wang J: Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism. Cancer Biol Ther. 19:825–834. 2018. View Article : Google Scholar : PubMed/NCBI
16	Lee YY, Yu YB, Gunawardena HP, Xie L and Chen X: BCLAF1 is a radiation-induced H2AX-interacting partner involved in γH2AX-mediated regulation of apoptosis and DNA repair. Cell Death Dis. 3:e3592012. View Article : Google Scholar : PubMed/NCBI
17	Savage KI, Gorski JJ, Barros EM, Irwin GW, Manti L, Powell AJ, Pellagatti A, Lukashchuk N, McCance DJ, McCluggage WG, et al: Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability. Mol Cell. 54:445–459. 2014. View Article : Google Scholar : PubMed/NCBI
18	Carmody SR and Wente SR: mRNA nuclear export at a glance. J Cell Sci. 122:1933–1937. 2009. View Article : Google Scholar : PubMed/NCBI
19	Zhang F, Wu J and Yu X: Integrator3, a partner of single-stranded DNA-binding protein 1, participates in the DNA damage response. J Biol Chem. 284:30408–30415. 2009. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
22	Chen P, Li J, Chen YC, Qian H, Chen YJ, Su JY, Wu M and Lan T: The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells. Cell Oncol (Dordr). 39:511–522. 2016. View Article : Google Scholar : PubMed/NCBI
23	Qin C, Zhang R, Lang Y, Shao A, Xu A, Feng W, Han J, Wang M, He W, Yu C and Tang J: Bclaf1 critically regulates the type I interferon response and is degraded by alphaherpesvirus US3. PLoS Pathog. 15:e10075592019. View Article : Google Scholar : PubMed/NCBI
24	Kinner A, Wu W, Staudt C and Iliakis G: Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 36:5678–5694. 2008. View Article : Google Scholar : PubMed/NCBI
25	Fragkos M, Jurvansuu J and Beard P: H2AX is required for cell cycle arrest via the p53/p21 pathway. Mol Cell Biol. 29:2828–2840. 2009. View Article : Google Scholar : PubMed/NCBI
26	Wang A, Ning Z, Lu C, Gao W, Liang J, Yan Q, Tan G and Liu J: USP22 induces cisplatin resistance in lung adenocarcinoma by regulating γH2AX-mediated DNA damage repair and Ku70/Bax-mediated apoptosis. Front Pharmacol. 8:2742017. View Article : Google Scholar : PubMed/NCBI
27	Meng X, Yang S and Camp VJA: The interplay between the DNA damage response, RNA processing and extracellular vesicles. Front Oncol. 9:15382020. View Article : Google Scholar : PubMed/NCBI
28	Huang Y, Liu C, Zeng WC, Xu GY, Wu JM, Li ZW, Huang XY, Lin RJ and Shi X: Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway. Biosci Rep. 40:BSR201927272020. View Article : Google Scholar : PubMed/NCBI
29	Chen S, Zhou Q, Guo Z, Wang Y, Wang L, Liu X, Lu M, Ju L, Xiao Y and Wang X: Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway. J Cell Mol Med. 24:1804–1821. 2020. View Article : Google Scholar : PubMed/NCBI
30	Kreis NN, Louwen F and Yuan J: The multifaceted p21 (Cip1/Waf1/CDKN1A) in cell differentiation, migration and cancer therapy. Cancers (Basel). 11:12202019. View Article : Google Scholar
31	Dell'Aversana C, Giorgio C, D'Amato L, Lania G, Matarese F, Saeed S, Costanzo AD, Petrizzi VB, Ingenito C, Martens JHA, et al: miR-194-5p/BCLAF1 deregulation in AML tumorigenesis. Leukemia. 31:2315–2325. 2017. View Article : Google Scholar : PubMed/NCBI
32	Li HL, Wang CY, Fu J, Yang XJ, Sun Y, Shao YH, Zhang LH, Yang XM, Zhang XL and Lin J: PTEN expression in U251 glioma cells enhances their sensitivity to ionizing radiation by suppressing DNA repair capacity. Eur Rev Med Pharmacol Sci. 23:10453–10458. 2019.PubMed/NCBI
33	Kamarudin MNA, Sarker MMR, Zhou JR and Parhar I: Metformin in colorectal cancer: Molecular mechanism, preclinical and clinical aspects. J Exp Clin Cancer Res. 38:4912019. View Article : Google Scholar : PubMed/NCBI
34	Yilmaz TE, Taşdemir M, Kaya M, Arican N and Ahishali B: The effects of magnesium sulfate on cyclophosphamide-induced ovarian damage: Folliculogenesis. Acta Histochem. 122:1514702020. View Article : Google Scholar : PubMed/NCBI
35	Warfel NA and El-Deiry WS: p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58. 2013. View Article : Google Scholar : PubMed/NCBI
36	Abbas T and Dutta A: p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI